CTI BioPharma Names Alan Burnett Therapeutic Area Lead, Myeloid Diseases

(RTTNews) - CTI BioPharma Corp. (CTIC) Monday announced the appointment of Alan K. Burnett to serve as the strategic leader for myeloid development. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University.

In his new role, Burnett will be responsible for creating and implementing the strategic development program for CTI BioPharma's compounds in myeloid malignancies. The major focus will be on supplementing CTI BioPharma's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.

Burnett will also help to identify promising earlier stage targets and therapeutics for potential development collaborations.

Burnett said, "CTI BioPharma's efforts to develop novel, targeted therapies for blood-related cancers are aligned with my own, as I believe there remains a significant unmet medical need for new therapies for patients, particularly older patients with AML and high-risk MDS."